Montek (Pertechnetate (99mtc) Sodium)

Sodium pertechnetate (99mTc) is taken up by cells that express sodium‑iodide symporters or have high blood flow. Once administered, it distributes to target tissues and emits gamma photons that are captured by a gamma camera, creating detailed images of physiological processes without altering cellular function.

The administered activity of Montek is determined by the prescribing physician based on the specific imaging protocol, patient weight, and the organ of interest. Dosing is individualized and follows established nuclear medicine guidelines to ensure optimal image quality while minimizing radiation exposure.

Montek should be avoided in pregnant patients unless the diagnostic benefit clearly outweighs the potential fetal radiation risk. For breastfeeding mothers, nursing should be paused for a period recommended by the nuclear medicine specialist, as the tracer can be secreted in breast milk.

To order Montek, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Compared with alternative agents such as iodine‑123 or technetium‑99m sestamibi, sodium pertechnetate offers rapid uptake in thyroid and salivary tissues and provides high‑quality images with a relatively short half‑life, reducing patient radiation dose. Choice of agent depends on the clinical question, organ of interest and imaging equipment.

Montek must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. The vial should remain in its original packaging until use, and any unused portion must be discarded according to local radiation safety regulations.

Montek is supplied as an injectable solution and is administered intravenously or, in specific ocular procedures, via an ocular route. The injection is performed by qualified nuclear medicine personnel under aseptic conditions, and imaging is typically started shortly after administration to capture optimal tracer distribution.

Serious risks include allergic reactions that can progress to anaphylaxis, radiation‑induced tissue injury in high‑uptake organs, and severe hypotension immediately following injection. Prompt recognition and appropriate medical intervention are essential to manage these rare but potentially life‑threatening events.

Montek is contraindicated in patients with known hypersensitivity to sodium pertechnetate or any component of the formulation, in pregnant women unless absolutely necessary, and in individuals who have received other radiopharmaceuticals within 24 hours, as this may compromise image quality and increase radiation exposure.